Sunday, July 3, 2022

Cancer Drug Truxima Receives License for Distribution in Colombia

In an extension of its partnership with Celltrion Healthcare, pharmaceutical provider Mundipharma has received a license to market and distribute its Truxima cancer treatment drug in Colombia.

(Photo credit: jarmoluk / Pixabay)

Truxima was also launched as the first “biosimilar monoclonal antibody” licensed for the treatment of cancer in various European markets in February, according to the Singapore-headquartered network of drug companies.

- Advertisement -

Mundipharma added that it is widely authorized in Europe for the treatment of diffuse large B cell Non-Hodgkin’s lymphoma, follicular lymphoma, chronic lymphocytic leukaemia, severe rheumatoid arthritis, and granulomatosis with polyangiitis and microscopic polyangiitis.

Raman Singh, chief executive officer of Mundipharma, said that this is a continuation of the firm’s push to distribute its drugs in new markets. “We are excited to expand our partnership with Celltrion Healthcare to include Truxima in Colombia,” said Singh. “As a core therapy for hematological malignancies, we see it as a good fit with our existing potfolio of products such as Difolta and Zevalin.”

 

- Advertisement -

FACT CHECK:
We strive for accuracy in its reports. But if you see something that doesn’t look right, send us an email. The Q reviews and updates its content regularly to ensure it’s accuracy.

Rico
"Rico" is the crazy mind behind the Q media websites, a series of onlinemagazines that includes TodayColombia.com. Rico brings his special kind of savvy to online marketing. His websites are engaging, provocative, informative and sometimes off the wall, where you either like or you leave it. The same goes for him, like him or leave him.There is no middle ground. No compromises, only a passion to present reality as he sees it!

Related Articles

- paying the bills -

MOST READ

- paying the bills -

WANT TO STAY UP TO DATE WITH THE LATEST!

Get our daily newsletter with the latest posts directly in your mailbox. Click on the subscribe and fill out the form. It's that simple!